News Quantified

NTLA – intellia therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..

Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]

Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..

Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing [Yahoo! Finance]

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? [Yahoo! Finance]

3.6%

BEAT

-22.7%

BEAT

-1.7%

BEAT

9.5%

BEAT

Chardan Capital

Canaccord Genuity

Form 424B5 Intellia Therapeutics,

Form 8-K Intellia Therapeutics, For: Apr 27

Form 8-K Intellia Therapeutics, For: Apr 07

Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC

Form 4 Intellia Therapeutics, For: Mar 01 Filed by: LEONARD JOHN M

Top News Gainers

2/27 Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool] 17.1%

10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%

2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%

11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%

4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%

6/7 Form EFFECT Intellia Therapeutics, 5.6%

2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%

10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%

3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%

7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%

Top News Decliners

3/13 Form 8-K Intellia Therapeutics, For: Mar 12 -17.6%

6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%

4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%

8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%

4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%

9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%

5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%

4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%

4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%

2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day